Clinical Trial Update: A Phase 4 Study to Evaluate Response to Treatment and Safety of Paliperidone Extended-Release in Participants With Schizophrenia [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the response to treatment and safety of Paliperidone Extended-Release in schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Paliperidone Extended Release (paliperidone extended-release)

Snippet

Sponsor: Janssen-Cilag Turkey | Conditions: Schizophrenia | Phase 4 | Status: COMPLETED